Abstract: Objective  To investigate the effect of load dosage rosuvastatin on src homology2containing inositol phosphatase 1 level (SHIP1) and prognosis in patients with nonST segment elevation myocardial infarction (NSTEMI) before and after percutaneous coronary intervention (PCI). Methods  A total of 96 patients with NSTEMI in Wuwei people's Hospital between June 2015 and April 2018 was randomly enrolled into the treatment group (48 cases) and the control group (48 cases). All patients in both groups were treated by PCI while patients in treatment group were treated by load dosage rosuvastatin (20 mg 12 h and 2 h before PCI,  respectively),  both groups were followedup for 180 days. The cTnI,  CKMB,  IL6,  TNFα,  IFNγ,  SHIP1,  miR155,  MACE and adverse drug reaction of both groups were comparatively analyzed. Results  No significant difference in cTnI and CKMB levels between the both groups was found before PCI (P＞0.05); at 12h after PCI,  the levels of cTnI and CKMB in both groups increased,  and decreased significantly at 24 hours after PCI,  among which,  the cTnI and CKMB of the treatment group was significantly lower than those of control group (P＜0.01). No significant difference in IL6,  TNFαand IFNγ levels was found between the two groups before PCI (P＞0.05),  at 24 h after PCI,  the levels of IL6,  TNFαand  IFNγ in in both groups increased while these indexes in the treatment group were significantly lower than those of the control group(P=0.000). No significant difference in relative expression of miR155 and SHIP1 was found between the two groups before PCI (P＞0.05),  the level of miR155 increased in both groups while it was lower in the treatment group than in the control group (P＜0.01) and the level of SHIP1 in the treatment group was higher than that of the control group(P＜0.01). The incidence of MACE within 180 days after PCI in the treatment group and in the control group was 16.67% (8/48) and 37.50% (18/48),  respectively,  while the risk of MACE of inpatients in the treatment group was significantly lower than that of control group (P=0.038). No significant difference existed in the total rate of  adverse drug reaction between the two groups (10.41% vs 14.59%, P=0.757). Conclusion   The preoperative load dosage of PCI can restore the myocardial enzyme level of NSTEMI patients after PCI treatment by inhibiting miR155/SHIP1 signal transduction pathway,  reduce inflammatory response and improve the prognosis of NSTEMI patients.

Key words: myocardial infarction, load dosagerosuvastatin, non STsegment elevation myocardial infarction, src homology2containing inositol phosphatase